Table 8

Selected Potential Patent Expirations for 2017

DrugBrand NameUse(s)
AtazanavirReyatazHIV infection
AtomoxetineStratteraAttention-deficit/hyperactivity disorder
AtovaquoneMepronPneumocystis jiroveci pneumonia
BortezomibVelcadeMultiple myeloma and mantle cell lymphoma
BuprenorphineButransPain and addiction to narcotic pain relievers
Carglumic acidCarbagluHyperammonemia
Caspofungin acetateCancidasFungal infections
CiclesonideOmnarisAllergies
CorticotropinActhar GelEndocrine disorders
Eletriptan hydrobromideRelpaxMigraine
ErtapenemInvanzInfections
Ezetimibe–simvastatinVytorinHypercholesterolemia
IloperidoneFanaptSchizophrenia
LovastatinAltoprevHypercholesterolemia
NelarabineArranonLeukemias and lymphomas
NitazoxanideAliniaDiarrhea associated with parasitic infection
Octreotide acetateSandostatin LAR DepotEndocrine disorders
Pegaptanib sodiumMacugenAge-related macular degeneration
PegvisomantSomavertAcromegaly
Rasagiline mesylateAzilectParkinson’s disease
Sumatriptan–naproxen sodiumTreximetMigraine
TestosteroneAxironHormonal supplement
VigabatrinSabrilSeizures
ZolpidemZolpimistSleep disorders